Abstract
Meijer L, Chrétien E and Ravel D. Leucettinib-21, a DYRK1A kinase inhibitor as clinical drug candidate for alzheimer's disease and down syndrome. J Alzheimers Dis 2024; 101(s1): S95-S113. DOI: 10.3233/JAD-240078
In the published version of Figure 2, there were errors in the chemical structures. The correct Figure 2 is shown below:
